Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
With the previous incumbent withdrawn from the market Ascendis hails a new hormone replacement for hypoparathyroidism.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Several key data readouts slated for the first quarter remain unannounced, from Roche, Lilly, Axsome and others, but the Covid-19 pandemic puts many at risk of delay.